Statistics reveal that nearly 100 domestic and multi-national pharma companies are conducting trials in India, a country in which less than 20 per cent of population is insured medically. Experts, Dr R K Sanghvi from the Indian Drug Manufacturers Association (IDMA), and Shweta Bharti, senior partner at Hammurabi & Solomon, discuss if India is an easy ground for conducting unethical clinical trials on account of the availability of a large genetic pool and high-quality hospitals here.
